Terminal · Institutions
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Deep Track Capital, LP (CIK 1856083) reported $6.87B across 66 reported positions in its SEC 13F filing for 2026-06-30. Largest positions: GH ($509.1M, 7.41%), IMVT ($359.9M, 5.24%), GPCR ($254.4M, 3.70%), PCVX ($250.0M, 3.64%), ALNY ($248.3M, 3.61%). Source: SEC Form 13F.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | GH | GUARDANT HEALTH INC | $509.1M | 7.41% | 3.4M | Added |
| 2 | IMVT | IMMUNOVANT INC | $359.9M | 5.24% | 9.3M | Trimmed |
| 3 | GPCR | STRUCTURE THERAPEUTICS INC | $254.4M | 3.70% | 4.7M | Added |
| 4 | PCVX | VAXCYTE INC | $250.0M | 3.64% | 4.3M | Hold |
| 5 | ALNY | ALNYLAM PHARMACEUTICALS INC | $248.3M | 3.61% | 825,000 | New |
| 6 | MANE | VERADERMICS INC | $245.9M | 3.58% | 2.0M | Added |
| 7 | GMAB | GENMAB A/S | $237.6M | 3.46% | 8.7M | Added |
| 8 | TARS | TARSUS PHARMACEUTICALS INC | $230.8M | 3.36% | 3.7M | Added |
| 9 | NUVL | NUVALENT INC | $220.2M | 3.21% | 1.8M | Added |
| 10 | ALKS | ALKERMES PLC | $209.6M | 3.05% | 4.0M | Added |
| 11 | OCUL | OCULAR THERAPEUTIX INC | $193.3M | 2.81% | 19.7M | Hold |
| 12 | BMRN | BIOMARIN PHARMACEUTICAL INC | $189.3M | 2.75% | 3.3M | Added |
| 13 | NRIX | NURIX THERAPEUTICS INC | $187.7M | 2.73% | 7.7M | Added |
| 14 | ORKA | ORUKA THERAPEUTICS INC | $183.3M | 2.67% | 1.9M | Trimmed |
| 15 | ALMS | ALUMIS INC | $178.6M | 2.60% | 6.3M | Trimmed |
| 16 | IONS | IONIS PHARMACEUTICALS INC | $174.4M | 2.54% | 2.2M | Added |
| 17 | VERA | VERA THERAPEUTICS INC | $171.6M | 2.50% | 4.0M | Trimmed |
| 18 | CMPS | COMPASS PATHWAYS PLC | $172.1M | 2.50% | 12.2M | Hold |
| 19 | AXSM | AXSOME THERAPEUTICS INC. | $171.3M | 2.49% | 700,000 | Trimmed |
| 20 | MLTX | MOONLAKE IMMUNOTHERAPEUTICS | $136.3M | 1.98% | 7.0M | Added |
| 21 | COAG | HEMAB THERAPEUTICS HLDGS INC | $132.3M | 1.93% | 3.6M | New |
| 22 | TNGX | TANGO THERAPEUTICS INC | $131.3M | 1.91% | 4.2M | Added |
| 23 | DFTX | DEFINIUM THERAPEUTICS INC | $129.4M | 1.88% | 2.8M | Trimmed |
| 24 | GRAL | GRAIL INC | $125.3M | 1.82% | 1.8M | Added |
| 25 | BCAX | BICARA THERAPEUTICS INC | $121.7M | 1.77% | 4.1M | Added |
Source: SEC Form 13F filings · as of 2026-06-30